PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Matsumoto, et al.

SERIAL NO.:

09/868,885

GROUP:

1646

FILED:

June 22, 2001

EXAMINER: N. S. Basi

FOR:

USE OF PEPTIDES

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT TRANSMITTAL

Transmitted herewith is an amendment for this application. 1.

STATUS

2.	Applic [] [X]	eant is a small entity. other than a small entity.	
	[X]	other than a small entity.	

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service [X] with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Signature

[]

Christine C. O'Day

(type or print name of person certifying)

mir C.h

05/21/2004 MBERHE

Date: ____5/17/04

00000038 09868885

01 FC:1251

110.00 OP

(Amendment Transmittal-page 1 of 4)

EXTENSION OF TERM

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) — If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has unless the timely-filed response placed the application in condition for allowance. Notice of December 10, 1985 (1061 O.G. been filed within the shortened statutory period, the period has ceased to run." Notice of December 10, 1985 (1061 O.G. 34-35).

NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings, and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b), as applicable)

(a) [X] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

Fee for other than small entity \$110.00 \$420.00 \$950.00 \$1,480.00 \$2,010.00	Fee for small entity \$55.00 \$210.00 \$475.00 \$740.00 \$1,005.00
	small entity \$110.00 \$420.00 \$950.00 \$1,480.00

Fee: \$ 110.00

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable)

		Chook				
[]	An extension for months has already been secured. The fee paid therefor of \$ is deducted from the total fee due for the total months of extension now requested.					
		Extension fee due with this request \$				
		OR				
(b)	[]	Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.				

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

•	The rec	(of Clairies (HAN A	
			> (O 1 2) CN/	IATT ENT	TTY	SM	ALL E	NTITY	
	(Col.1)	(Co	ol. 2) (Col. 3) SM	ALL ENI	<u> </u>				
	Clai Remai Aft Amend	ning er lment	Highest No. Previously Paid For	Present Extra	Rate x \$9 =	Addit. Fee	OR	Rate x \$18 =	Addit. Fee \$
otal_		* Minus	3		x \$42 =	\$0		x \$84 =	<u>\$0</u>
ndep.		* Minu	S		+ \$140 =	\$0		+ \$280 =	\$ 0
Fi	rst Preser	tation of M	Iultiple Depende	nt Claim	Ι ΨΧΙΟ	••			
					Total Addit. Fee	\$	OR	Total Addit. Fee	\$
WAR!	of a pric	or amendment	eviously Paid For" I viously Paid For" (I or the number of cla rejection or action tof form which has	(0.1.113)	dmants may h	e made can	celing cl	aims or complyi	
		·			(d), as applic				
	(c)		No additional fee	()K				
	(d)	[]	Total additional	fee for clai	ms required S	S			
				FEE PA	AYMENT				
5.	[X] []	Charge	d is a check in the Account Nocate of this trans		the sur	 n of \$.	
					-TOTENION				

FEE DEFICIENCY

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6.	[X]	If any additional extension and/or fee is required, charge Account No04-1105
6.	[X]	If any additional extension and/or fee is required, charge see

AND/OR

[X] If any additional fee for claims is requi	[X] If any additional fee for claims is required, charge Account No04-1105				
	SIGNATURE OF PRACTITIONER				
Reg. No. 38,256	Christine C. O'Day (type or print name of practitioner)				
Tel. No. (617) 439-4444	EDWARDS & ANGELL, LLP P.O. Box 55874 P.O. Address				
Customer No. 21874	Boston, Massachusetts 02205				



Docket No. 55999 (46342)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Matsumoto, et al.

SERIAL NO.:

09/868,885

GROUP:

1646

FILED:

June 22, 2001

EXAMINER: N. S. Basi

FOR:

USE OF PEPTIDES

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

AMENDMENT

Applicants are in receipt of the Office Action dated January 15, 2004. Kindly amend the above-identified application as set forth below.

Amendments to the specification begin on page 2 of this paper.

Amendments to the claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 5 of this paper.